Go Ad-Free
    My Alerts
    Budget Express 2026

    co-presented by

    • JIO BlackRock
    HomeNewsNeuclone

    Neuclone

    Jump to

    • Lupin sees more development on NeuClone deal in 5-6 qtrs

      S Ramesh, CFO of Lupin, in an interview with CNBC-TV18’s Latha Venkatesh and Gautam Broker, said that this agreement might bear fruit in five-six quarters. He also stated that Lupin wants a positive development in this particular area.

    • Lupin signs licensing deal with Sydney co

      Drugmaker Lupin said on Wednesday it signed a licensing agreement with Sydney-based private speciality lifescience company NeuClone P Ltd for cell line technology.

    • Lupin inks licensing agreement with NeuClone; stock down

      Lupin inks licensing agreement with NeuClone for Cell Line Tech, reports CNBC-TV18. It touched an intraday high of Rs 476 and an intraday low of Rs 460.60. At 14:06 hrs the share was quoting at Rs 464.35, down Rs 5.50, or 1.17%.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347